July 25, 2026 a 09:00 pm

LLY: Analysts Ratings - Eli Lilly and Company

Historical Stock Grades

In analyzing the historical stock grades for Eli Lilly, we observe consistent support in the "Buy" category, alongside notable recommendations for "Strong Buy," reflecting confidence in the firm's strategy and market position. However, minor involvements in "Hold" and "Sell" ratings suggest a need for strategic scrutiny as market dynamics evolve.

Rating	Count	Score Distribution
Strong Buy	6
Buy	17
Hold	5
Sell	1
Strong Sell	1

Sentiment Development

Throughout the past months, sentiment for Eli Lilly has predominantly trended towards "Buy," with a stable yet slightly fluctuating number of "Strong Buy" recommendations. Of note, there has been a gradual rise in "Hold" ratings, implying a cautious tone among some analysts.

• The overall number of analyst ratings has remained relatively steady over recent months.
• "Strong Buy" ratings have seen minor fluctuations but maintain a significant portion of sentiment.
• There is a slight increase in "Hold" recommendations, indicating emerging caution.

Percentage Trends

The percentage of "Buy" recommendations continues to dominate, yet subtle shifts indicate changing analyst perspectives. The most pronounced shift is an increase in "Hold" percentages, with "Strong Buy" ratings displaying slight variability. This may signal a tempering of bullish perspectives in the short term.

• From the beginning of 2025 to mid-2026, there is a noticeable increase in "Hold" percentages.
• "Strong Buy" percentages slightly reduced, reflecting potential market saturation concerns.
• "Buy" percentages remain robust, underpinning solid confidence in Eli Lilly's market strategy.

Latest Analyst Recommendations

Recent recommendations from top firms have predominantly maintained existing positions, reflecting a period of stability for Eli Lilly. The majority of analysts have reaffirmed their "Buy" ratings, consistent with historical sentiment data.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-15	Buy	Buy	Citigroup
2026-07-14	Outperform	Outperform	Bernstein
2026-07-13	Buy	Buy	Guggenheim
2026-07-13	Buy	Buy	UBS
2026-07-10	Buy	Buy	B of A Securities

Analyst Recommendations with Change of Opinion

Changes in analyst opinions have occurred, reflecting nuanced strategies in response to Eli Lilly's market positioning. While some analysts have downgraded their recommendations, others see increased opportunity, yielding a dynamic mix of perspectives.

Date	New Recommendation	Last Recommendation	Publisher
2026-03-17	Reduce	Hold	HSBC
2026-02-10	Buy	Hold	Freedom Broker
2025-11-10	Outperform	Market Perform	Leerink Partners
2025-11-10	Hold	Buy	Freedom Capital Markets
2025-11-10	Hold	Buy	Freedom Broker

Interpretation

The market's overall assessment of Eli Lilly shows stability, with a strong inclination towards buying amidst minor fluctuations in sentiment. The mix of recommendations suggests confidence in the company's strategic path, despite concerns resulting in more "Hold" ratings. Growing caution from some analysts might point to market uncertainties, while consistent "Buy" recommendations reflect trust in Eli Lilly's innovations and market performance. The landslide of "Buy" and "Strong Buy" suggests that analyst opinions are predominantly stable, reflecting well-founded confidence in the company's longevity and potential for value creation.

Conclusion

Eli Lilly and Company remains a resilient entity within the pharmaceutical landscape, marked by strong analytical support. The balance between "Buy" and increased "Hold" signals suggests a thoughtful evaluation by analysts of growth prospects tempered by market volatility. While embracing innovation and global outreach, the company's strategic alliances may mitigate potential risks, reinforcing its competitive edge. Analyst sentiment, while slightly more cautious, underscores the firm's robust positioning, anticipating continued evolution and adaptation to market demands.